Ulcerative Colitis Back Pain: When the Bowel Reaches the Spine

He had carried low back pain for eleven years, four MRIs, two injections, a course of gabapentin and a surgeon who advised against operating. He had also carried a diagnosis of ulcerative colitis since his mid-thirties. Across all those visits, nobody put the two in one sentence.

Ulcerative colitis back pain is not rare and it is not mysterious. It is missed because the bowel and the spine are billed by different specialists. I am Dr. Gurpreet Singh Padda, MD, MBA, MHP, and I tell this case in the video for Chapter 11 of The Angry Gut, the book I wrote with Ami Michelle Grimes. Here I want to give you what the video could not fit: the numbers on how often it happens, what the inflamed gut is doing while nobody looks, and what actually changes the course.

Why ulcerative colitis back pain gets missed

A gastroenterologist is paid to scope the colon. A spine surgeon is paid to read the lumbar MRI. Each visit is complete on its own terms, and the patient becomes the only person carrying the whole file. His scans showed some lost disc height, a bulge, and a bright endplate band one radiologist called a Modic change. Those findings are common in people without any pain. They told everyone where it hurt. None of them said why.

That is an incentive problem, not a knowledge problem. The data connecting bowel and spine have been published for decades.

How often the bowel and the spine share a patient

Pooled across 71 studies, people with inflammatory bowel disease had sacroiliitis at 10%, ankylosing spondylitis at 3% and peripheral arthritis at 13%. A later meta-analysis of 52 studies and 352,454 patients found at least one problem outside the gut in 24% overall, 27% in ulcerative colitis and 35% in Crohn’s disease, with axial joint involvement at similar rates in both.

Genetics sorts the risk. In ulcerative colitis, carrying HLA-B27 raised the relative risk of ankylosing spondylitis to 22.17, and 68.29% of colitis patients who developed it carried the gene. Only three pooled studies reported HLA-B27 status at all, so that estimate is wide, but its direction is not in doubt.

The arrow also runs the other way. A Korean team scoped 108 people with ankylosing spondylitis who had no known bowel disease. Forty had inflammatory lesions, and seventeen had an actual disease: Crohn’s in twelve, intestinal tuberculosis in four and ulcerative colitis in one. Even among those scoped as routine screening, 17.6% had abnormal lesions, mostly erosions and ulcers. That study was retrospective and single-center, and anti-inflammatory drugs can erode the bowel on their own, but a spine clinic that never asks about the gut is working half-blind.

What the inflamed gut does while nobody watches

Two biological drivers carry the signal. The first is bacteria. Rats engineered to carry human HLA-B27 develop gut and joint inflammation, and when they are raised germ-free they develop neither. That is animal work, a proof of principle rather than a human result, but it says the flora are required for the arthritis in a susceptible host.

The second is the immune alarm. In gut biopsies from 40 people with ankylosing spondylitis, inflammasome genes ran roughly tenfold apart from controls: NLRP3 at a fold induction of 22.2 against 2.33, CASP1 at 24.8 against 2.53. Bacteria stuck to and pushing into the lining scored higher too, and tracked the alarm in circulating white cells. The link to spinal disease activity was real but modest, a correlation of 0.28, which is a hint and not a mechanism.

The drug trials show the axis is not one lever. Interleukin-23 is raised in the spondylitis gut while interleukin-17 is not. A drug that blocks interleukin-17A helps the spine, yet in 59 Crohn’s patients it did worse than placebo, and 18 stopped early. The same immune pathway, read in two organs, wants opposite things. The social driver sits on top: a system that assigns each organ to a different billing code will keep prescribing for one while the other flares.

The four questions that find inflammatory back pain

In this man’s case, the most useful tool was not a fifth scan. It was a history. Does the pain wake you in the second half of the night? Are you stiff for more than half an hour in the morning? Does it ease with movement and worsen with rest, the opposite of a mechanical back? Has anyone connected it to your bowel?

He answered yes to the first three and no to the last. That pattern is what inflammatory back pain looks like, and it points toward an HLA-B27 test, a proper look at the sacroiliac joints and a rheumatologist, alongside tighter control of the colitis. The proven road from bowel to spine runs through inflammation, so cooling the bowel is spine treatment.

Where injections fit, and where they stop

His injections were not a mistake. An injection can quiet an inflamed nerve root for weeks or months, and a man who cannot sit through dinner cannot do anything else we ask of him. I explain the biology in what an epidural steroid injection actually does, and when placement precision matters in why injecting blindly is accepting failure.

The failure was the injection with nothing behind it. For eleven years, the window each one opened was never used to address the bowel, the immune system or the terrain. Surgery had been advised against in his case, and it was never going to reach an inflammatory driver.

Why antibiotics are the wrong reflex

He came in asking for antibiotics, because he had read that bacteria live in the disc. The first trial of that idea, in patients with Modic type 1 changes, reported disability scores falling from 15 to 11 to 5.7 on amoxicillin-clavulanate while placebo went 15, 14, 14. Two of its authors had been directors of companies commercializing the protocol, which they did not declare.

A larger trial then set 4 points as the smallest difference that matters to a patient and found a difference of 1.6. Drug-related side effects ran 56% against 34%. My practice does not prescribe antibiotics for back pain. The bacteria may be real, but a disc with no blood supply is barely reached by a pill, and the gut that feeds the terrain is exactly what you should not carpet-bomb.

Treating the pipe behind the wall

Treating his spine without his gut would be repainting a wall while the pipe behind it leaks. The pipe is his intestinal barrier, the subject of the leaky gut chapter. Refined, acellular carbohydrates starve the bacteria that make short-chain fatty acids, the fuel the lining depends on. Industrial seed oils feed metaflammation. Night pain steals the deep sleep in which the body turns down inflammatory signaling, which feeds more night pain. Each of those is modifiable, and each is part of treatment, not aftercare.

The disc-microbiome end of this story is a lower evidence tier: bacterial DNA in discs and a gut-to-disc route watched in mice. The bowel-to-spine inflammation is proven across dozens of studies. We treat both, because the patient has both. For the immune groundwork behind this, see why vitamin D is a hormone. For how far bowel inflammation travels beyond the spine, continue to the waistline that predicted a leaking brain. Every study here, with full numbers and limits, is in the Chapter 11 Deep Dive.

Frequently asked questions

Can ulcerative colitis cause back pain?

Yes. Across 71 studies, people with inflammatory bowel disease had sacroiliitis at about 10% and ankylosing spondylitis at 3%. In ulcerative colitis, carrying the HLA-B27 gene raised the relative risk of ankylosing spondylitis about twenty-two-fold. The pain usually feels inflammatory: morning stiffness, night waking and relief with movement. How that spinal condition is recognized is covered on our ankylosing spondylitis page.

What does inflammatory back pain feel like?

It tends to wake people in the second half of the night, leaves them stiff for more than half an hour in the morning, and improves with movement while worsening with rest. Mechanical back pain usually does the opposite. If that pattern fits and you also have bowel symptoms or a bowel diagnosis, raise both together. The sacroiliac joint is a frequent source, explained in when low back pain is actually the sacroiliac joint.

Should someone with IBD and back pain get an HLA-B27 test?

It is a reasonable question to bring to your physician. Among colitis patients who went on to develop ankylosing spondylitis, 68.29% carried HLA-B27. A positive result does not diagnose anything alone, but combined with an inflammatory pain history and a look at the sacroiliac joints it can route you to a rheumatologist years sooner. The immune logic behind gene-driven inflammation continues in why your immune system is not confused.

Will antibiotics help back pain with Modic changes?

Not in a way that has held up. After an early positive trial whose authors had an undeclared commercial interest, a larger and better-controlled trial found a benefit of 1.6 points against a pre-set threshold of 4, with more side effects on the drug. A Modic change is common in people without pain, so the scan alone is not a reason to treat. Why imaging misleads is covered in your MRI is lying to you.

Can a spine problem be a sign of hidden bowel disease?

Sometimes. When 108 people with ankylosing spondylitis and no known bowel disease were scoped, forty had inflammatory lesions and seventeen had a diagnosable condition such as Crohn’s disease. If you have spinal inflammation plus loose stools, urgency, blood, mouth ulcers or unexplained weight loss, ask whether your bowel has actually been examined. Chronic immune activation from hidden sources is discussed in pathogen burden and injuries that will not heal.

Sources

1. Karreman, M. C., Luime, J. J., Hazes, J. M. W., & Weel, A. E. A. M. (2017). The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn’s & Colitis, 11(5), 631–642. https://doi.org/10.1093/ecco-jcc/jjw199
2. Kilic, Y., Kamal, S., Jaffar, F., Sriranganathan, D., Quraishi, M. N., & Segal, J. P. (2024). Prevalence of extraintestinal manifestations in inflammatory bowel disease: A systematic review and meta-analysis. Inflammatory Bowel Diseases, 30(2), 230-239. https://doi.org/10.1093/ibd/izad061
3. Lin, A., Tan, Y., Chen, J., Liu, X., & Wu, J. (2023). Development of ankylosing spondylitis in patients with ulcerative colitis: A systematic meta-analysis. PLoS One, 18(8), e0289021. https://doi.org/10.1371/journal.pone.0289021
4. Ahn, S. M., Kim, Y.-G., Bae, S.-H., Lim, D.-H., Hong, S., Park, S. H., Lee, C.-K., & Yoo, B. (2017). Ileocolonoscopic findings in patients with ankylosing spondylitis: A single center retrospective study. The Korean Journal of Internal Medicine, 32(5), 916-922. https://doi.org/10.3904/kjim.2015.313
5. Taurog, J. D., Richardson, J. A., Croft, J. T., Simmons, W. A., Zhou, M., Fernández-Sueiro, J. L., Balish, E., & Hammer, R. E. (1994). The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. The Journal of Experimental Medicine, 180(6), 2359–2364. https://doi.org/10.1084/jem.180.6.2359
6. Guggino, G., Mauro, D., Rizzo, A., Alessandro, R., Raimondo, S., Bergot, A.-S., Rahman, M. A., Ellis, J. J., Milling, S., Lories, R., Elewaut, D., Brown, M. A., Thomas, R., & Ciccia, F. (2021). Inflammasome activation in ankylosing spondylitis is associated with gut dysbiosis. Arthritis & Rheumatology, 73(7), 1189-1199. https://doi.org/10.1002/art.41644
7. Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., Karczewski, J., Pezous, N., Bek, S., Bruin, G., Mellgard, B., Berger, C., Londei, M., Bertolino, A. P., Tougas, G., & Travis, S. P. L. (2012). Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 61(12), 1693–1700. https://doi.org/10.1136/gutjnl-2011-301668
8. Albert, H. B., Sorensen, J. S., Christensen, B. S., & Manniche, C. (2013). Antibiotic treatment in patients with chronic low back pain and vertebral bone edema (Modic type 1 changes): a double-blind randomized clinical controlled trial of efficacy. European Spine Journal, 22(4), 697–707. https://doi.org/10.1007/s00586-013-2675-y
9. Dean, B. J., & Davies, B. M. (2013). No conflict of interest? European Spine Journal, 22(8), 1700. https://doi.org/10.1007/s00586-013-2899-x
10. Bråten, L. C. H., Rolfsen, M. P., Espeland, A., Wigemyr, M., Aßmus, J., Froholdt, A., Haugen, A. J., Marchand, G. H., Kristoffersen, P. M., Lutro, O., Randen, S., Wilhelmsen, M., Winsvold, B. S., Kadar, T. I., Holmgard, T. E., Vigeland, M. D., Vetti, N., Nygaard, Ø. P., Lie, B. A., … Zwart, J.-A. (2019). Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial. BMJ, 367, l5654. https://doi.org/10.1136/bmj.l5654

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 11 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP